Discover investment opportunities in Best Microcap Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Microcap Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Microcap Stocks using our Smart AI Filter.
5 stocks found for "Best Microcap Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.09 | ±100.0% | -0.4 | 0.00% | |||
1.01 | ±62.0% | 25.4 | 0.00% | |||
0.70 | ±100.0% | 11.6 | 0.00% | |||
0.61 | ±100.0% | -0.8 | 158.73% | |||
1.09 | ±100.0% | -8.8 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
The heavy selling pressure might have exhausted for Citius Pharmaceuticals, Inc. (CTXR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Read moreExicure Inc (NASDAQ: XCUR) has reported year-end cash, cash equivalents, and short-term investments of $48.3 million that will fund its current operations into Q4 of 2022. The Company said that it expects to continue to generate operating losses and negative operating cash.
Read morePAVmed Inc (NASDAQ: PAVM) announced the successful implantation of its PortIO Intraosseous Infusion System in three patients as part of a first-in-human (FIH) clinical study of up to 40 patients. No complications have occurred.
Read moreQ: How can investors assess the potential growth of TELL in the natural gas sector?
A: TELL, or Tellurian Inc., focuses on natural gas and liquefied natural gas infrastructure. Investors may consider its strategic positions in LNG markets and partnerships. Market conditions, geopolitical factors, and demand for cleaner energy can affect growth prospects.
Q: What are some risks associated with investing in VXRT's biotech ventures?
A: VXRT operates in the volatile biotech sector, facing risks like regulatory approval hurdles, clinical trial results, and potential competition. Investors often evaluate R&D pipelines and partnership deals to gauge risk levels.
Q: In what ways could NNDM appeal to tech-focused investors?
A: NNDM, or Nano Dimension, specializes in additive electronics and 3D-printed electronics. Its appeal may lie in innovative technology and potential applications in various tech industries. However, the company operates in a rapidly evolving market.
Q: How does BBLG's environmental focus potentially benefit its growth strategy?
A: BBLG, engaged in sustainable solutions, may benefit from growing environmental awareness and regulatory shifts promoting eco-friendly products. Its market position in clean technology can be advantageous amid increasing ESG considerations.
Q: What should investors consider when evaluating the stability of SPPI's financial health?
A: SPPI, or Spectrum Pharmaceuticals, faces challenges typical of biotech firms, like funding R&D and achieving drug approvals. Financial indicators such as cash reserves and partnerships might provide insights into its stability.
Q: Can SURF's innovations in the pharmaceutical sector appeal to long-term investors?
A: SURF, a biopharma company, focuses on developing specialized therapies. Long-term investors might find its innovative drug pipeline appealing, though they should weigh this against potential regulatory and market competition challenges.